Navigation Links
Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
Date:9/8/2009

LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today reaffirmed its previously announced guidance for fiscal year 2009. The Company expects to meet or exceed its goals of $111 to $116 million in revenue and operating income of $40 to $43 million for the fiscal year ending June 30, 2009.

"We plan to report our annual results for the fiscal year 2009 by the end of this month and are pleased to reaffirm we are on track to achieve our financial goals," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo. "We continue to revamp the production lines which we acquired from Hongrui earlier this year. We expect this project to be completed in May 2010, when we should be able to begin mass production of other profitable TCM products. Thus, we continue to feel confident in maintaining a healthy growth rate over the long term."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
2. Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
8. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
9. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
10. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
11. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... Waxhaw, NC (PRWEB) , ... August 22, 2017 ... ... device company focused on the development and distribution of highly differentiated spinal implant ... Luke Maher brings 15 years of spinal device industry experience to ...
(Date:8/22/2017)... ... August 22, 2017 , ... One of ... the practice of opioid-dose sparing. Opioid-dose sparing refers to the reduction of opioid ... with non-steroidal anti-inflammatory drugs (NSAIDs). , The potential for new therapies to replace ...
(Date:8/22/2017)... MA (PRWEB) , ... August 22, 2017 , ... ... new service pipeline built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox ... source GUIDE-Seq computation pipeline to be provide scientists with easy to understand reports, ...
(Date:8/21/2017)... (PRWEB) , ... August 20, 2017 , ... ... Journal of Biomedical Optics (JBO) starting 1 January 2018. The journal is published ... Biomedical Optics publishes papers on the use of modern optical technology for improved ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO┬«). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):